Moleculin Biotech, Inc. (LON:0K2H)

Market Cap	9.43M +135.4%
Revenue (ttm)	n/a
Net Income	-38.25M
EPS	-56.64
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	148
Average Volume	740
Open	4.280
Previous Close	4.350
Day's Range	4.020 - 4.280
52-Week Range	3.150 - 90.500
Beta	1.62
RSI	41.00
Earnings Date	Mar 23, 2026

About Moleculin Biotech

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 17
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0K2H

Financial Performance

Financial numbers in USD